By their very nature, clinical studies in rare disease populations pose unique scientific, medical, ethical, and logistical challenges. Innovative solutions to overcome these hurdles are desperately needed so that clinical studies can be completed in a timely manner to bring these new therapies to rare disease patients. This case study outlines PRA’s solutions.